GSK 5462688
Alternative Names: GSK-5462688Latest Information Update: 11 Mar 2024
At a glance
- Originator GSK
- Class Oligonucleotides; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alpha 1-antitrypsin deficiency
Most Recent Events
- 07 Feb 2024 Phase-I clinical trials in Alpha 1-antitrypsin deficiency (unspecified route), prior to February 2024 (GSK pipeline, February 2024)